Kornimate/medical-research-clean huggingface dataset:
impact of particulate matter in chronic obstructive pulmonary disease patients

Conditions: COPD

Summary: a prospective study will be conducted in patients with copd. the investigators will suggest about intervention for preventing in recurrence and aggravation of adult chronic respiratory disease due to exposure to particulate matter.

study trends and intervention plans related to particulate matter exposure and adult chronic respiratory disease in literature measurement of particulate matter exposure by individual activities and collection of clinical information linkage between individual particulate matter exposure and clinical information investigation about effectiveness of intervention to avoid particulate matter

Eligibility criteria:
inclusion criteria: * copd over 40 years of age * patients with pulmonary function tests with forced expiratory volume at 1 second / forced vital capacity \<0.7 and forced expiratory volume at 1 second1 \<80% exclusion criteria: * patients under the age of 18 * elderly people over 80 years old * people with respiratory symptoms with modified medical research council dyspnea scale 0 * persons who do not understand the brief description of the particulate matter exposure device * a person who does not agree to the study
monitoring of allergic and asthmatic symptoms in patients taking dietary supplements joalis bambi bronchi and joalis bambi analerg

Conditions: Children

Summary: reduction of the total ige antibody, improved vital capacity and lung volume measured by spirometry. improving quality of life observed in the visual analogue scale (vas).


Eligibility criteria:
inclusion criteria: * subjects with confirmed asthma bronchiale i-iii. degrees in possible combination with other allergic symptoms treating with classic pharmacological treatment * 9-18 years * signed infromed conset exclusion criteria: * subjects who have previously used a food suplemts joalis * subjects with known intolerance or hypersensitivity to the components of food supplements * subjects with alcohol abuse or drugs at the time of recruitment into the study * subjects enrolled in another clinical trial in the last 1 month before enrollment in this study * subjects in a situation which in the opinion of a doctor may interfere with optimal participation in the study or can pose a risk to the subjects * pregnant girls, lactating girls and girls of childbearing age without adequate contraception

Keywords: food supplements asthma bronchiale
distribution of highly sensitive troponin in the critically unwell & associated mortality

Conditions: Myocardial Infarction; Myocardial Injury

Summary: the current diagnostic criteria for a heart attack require evaluation of a patient's symptoms and ecg but importantly a blood test called troponin. with advancing technology this test has become more sensitive and is now called a high sensitivity troponin. this is a very effective way of rapidly excluding a heart attack if the test is negative. however there are a number of causes of a raised high sensitivity other than a heart attack, particularly critical illness states. in the absence of features of a heart attack an abnormal result therefore suggests that the heart is inflamed or unwell causing the release of high sensitivity troponin. the dignity study will examine the consequences of high sensitivity troponin elevation in patients in intensive care and assess whether it has a role as a biomarker for predicting outcome.


Eligibility criteria:
inclusion criteria: * adult patients (aged 18 years or older) admitted to any of the three intensive care facilities on site (general, cardiac and neurosciences) * biochemistry samples already taken as part of routine clinical care during the icu stay exclusion criteria: * patients aged less than 18 years * no biochemistry samples taken within the icu stay
arrhythmias detection in a real world population

Conditions: Appropriate and Inappropriate Shock Therapy With ICD; Arrhythmias Detection

Summary: the study is a prospective multicenter registry. consecutive patients with indications of implant / replacement or upgrade of implantable cardioverter defibrillator (icd) will be enrolled. the primary objective of the study is to determine the predictors of appropriate anti-tachycardia therapy (with shock) in a non-selected population of patients implanted with an icd. secondary objectives of the study are: * the incidence of anti-tachycardia therapies; * the predictors of inappropriate therapy and onset of arrhythmia burden; * the adherence to the current guidelines in the italian clinical practice; * the predictors of heart failure (hf) onset and response to cardiac resynchronization therapy (crt).


Eligibility criteria:
inclusion criteria: * patient implanted with a subcutaneous (s)- ventricular chamber (vr)- dual chamber (dr) - or cardiac resynchronization therapy (crt) defibrillator (this study will utilize all the market released crt-d or vr/dr-icd systems and leads) * patient is willing and able to sign an authorization to use and disclose health information or an informed consent * patient must be able to attend all required follow-up visits at the study center for at least 12 months exclusion criteria: * patient is participating in another clinical study that may have an impact on the study endpoints * women who are pregnant or plan to become pregnant

Keywords: implantable cardioverter-defibrillators ventricular fibrillation ventricular tachycardia
nab-paclitaxel versus topotecan as second-line treatment for patients with extensive stage small cell lung cancer

Conditions: Extensive Stage Small Cell Lung Cancer

Summary: the purpose of this study is to compare the efficacy and safety of nab-paclitaxel with topotecan as second-line treatment for patients with extensive stage small cell lung cancer.


Eligibility criteria:
inclusion criteria: 1.18 to 75years, male or female; 2.histological or pathological diagnosis of small cell lung caner; 3.progression or relapse after first-line chemotherapy, extensive disease; 4.ecog performance status of 0-2; 5.life expectancy of 3 months or more; 6.patient must be accessible for treatment and follow-up; 7.for women of child-bearing age, the pregnancy test results (serum or urine) within 72 hours before enrolment must be negative. they will take appropriate methods for contraception during the study; 8.signed informed consent. exclusion criteria: 1. symptomatic brain metastases; 2. uncontrolled serious medical conditions that, in the opinion of the investigator, would affect the ability of the subject to receive the study regimen, such as concomitant serious medical conditions, including severe heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.; 3. have dementia, altered mental state or any mental illness that would prevent understanding or informed consent or fill out questionnaires; 4. received any investigational drug within 30 days of the planned first dose of this study treatment. 5. prior grade ≥ 2 peripheral neuropathy(according to (nci ctcae), version 5.0); 6. known to be hypersensitive, highly sensitive, or intolerant to study-related medications or their excipients; 7. have malignant tumors in the past 5 years, except for clinically cured basal cell or squamous cell skin cancer, local prostate cancer after radical operation, and ductal carcinoma in situ after radical operation; 8. bone marrow function: neutrophils \ 1.5×uln; ast and alt \> 2.5×uln or \> 5×uln in the presence of hepatic metastasis; total bilirubin \>1.5×uln; 9. patients need other anti-tumor drugs; 10. known hiv, hepatitis b/c virus positive ; 11. the researchers considered the patients who were not suitable for enrollment.

Keywords: nab-paclitaxel topotecan
hydroxychloroquine efficacy in chronic urticaria

Conditions: Chronic Urticaria

Summary: this study is for those people with difficult to treat hives. we are investigating whether or not a different medication, hydroxychloroquine, works to treat a certain type of hives. hydrochloroquine is currently approved by the food and drug administration (fda), for treating arthritis, therefore it is considered investigational in this study. hypothesis: hydroxychloroquine will prove to have an efficacious response in terms of urticarial symptoms, on patients with chronic urticaria.

our research question is: is hydroxychloroquine an efficacious medicine to use in patients with chronic urticaria? answering this question should help allergists treat chronic urticaria with a more evidence based approach. to date there has one been one prospective trial evaluating hydroxychloroquine in hives, and although it showed a trend towards efficacy (0.05\<p\<0.10), it was not statistically significant. there have been case series, and anecdotal reports which seem to demonstrate efficacy of chloroquine in chronic urticaria. because of these reports hydroxychloroquine is often the first medication used in patients with chronic hives that are refractory to standard therapy of antihistamines. we believe an evidence based answer to this question will be an important step towards improved treatment of this disease. we plan to ascertain the efficacy of hydroxychloroquine by completing a randomized double blinded placebo controlled study of treatment in patients with chronic urticaria. we will be measuring an urticarial score to evaluate hive symptoms. we will be measuring them at baseline, and at the end of the study to note change in drug vs placebo.

Eligibility criteria:
inclusion criteria: * inclusion: 1. age \>18, age\<65 2. chronic urticaria refractory to treatment with standard anti-histamines 3. minimum urticaria score exclusion criteria: * exclusion: 1. pregnancy 2. vasculitis 3. trigger induced urticaria 4. food intolerance 5. malignancy 6. kidney or liver dysfunction 7. systemic diseases 8. hypersensitivity to hydroxychloroquine

Keywords: chronic urticaria hives hydroxychloroquine
26-week open study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in hypertension

Conditions: Hypertension

Summary: the primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40mg/amlodipine 10mg (t40/a10) or telmisartan 80mg/amlodipine 10mg (t80/a10) during open-label treatment for at least six months. an additional objective is to assess the efficacy and safety of concomitant administration of either t40/a10 or t80/a10 with any other therapies commonly used in the treatment of hypertension. the primary endpoint is the proportion of patients achieving dbp control (defined as mean seated dbp \< 90 mmhg at trough i.e. approximately 24 hours after last dose of study treatment) at six months of treatment or at last trough observation during the treatment period (i.e. last trough observation carried forward).


Eligibility criteria:
inclusion criteria: - diagnosis of essential hypertension exclusion criteria: * pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential). * development of any condition in the preceding trial that could be worsened by telmisartan 40mg/amlodipine 10mg (t40/a10) or telmisartan 80mg/amlodipine 10mg (t80/a10). * discontinuation from the preceding trial. * known or suspected secondary hypertension. * mean seated systolic blood pressure (sbp) \>= 180 mmhg and/or mean seated diastolic blood pressure (dbp) \>= 120 mmhg at any visit. * any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant. * clinically relevant hyperkalaemia. * uncorrected volume or sodium depletion. * primary aldosteronism. * hereditary fructose or lactose intolerance. * symptomatic congestive heart failure. * patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme (ace) inhibitors or angiotensin receptor blockers (arbs). * any new drug or alcohol dependency since signing consent of the preceding trial. * concurrent participation in another clinical trial or any investigational therapy since completing the preceding trial. * hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve. * known allergic hypersensitivity to any component of the formulations under investigation. \[includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine calcium channel blockers (ccbs).\] non-compliance with study medication (defined as \ 120%) during the preceding trial. * administration of arbs or dihydropyridine ccbs (apart from trial medication). any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine.
sibutramine to reduce weight gain and improve smoking cessation rates

Conditions: Cardiovascular Diseases; Heart Diseases; Obesity

Summary: the purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking.

background: cigarette smoking poses a serious but preventable health risk. behavioral smoking cessation programs have been shown to help individuals quit smoking. however, concerns about post-cessation weight gain have been reported as a significant barrier to quitting for many smokers. recently, sibutramine, a new serotonin and norepinephrine reuptake inhibitor drug, has received fda approval to help people lose weight. since sibutramine affects neurotransmitters that are important in regulating body weight, it is reasonable to hypothesize that it may decrease post-cessation weight gain in overweight and obese smokers who quit smoking. to date, there have been no studies that compare sibutramine to a placebo, as a way to reduce post-cessation weight gain among overweight and obese smokers who take part in a behavioral smoking cessation program. therefore, whether sibutramine is effective at reducing post-cessation weight gain in these smokers is unknown. further, given the neuropharmacologic effects of sibutramine, it is reasonable to speculate that this medication could also be effective in helping individuals quit smoking both initially and in the long term. it is possible that the use of sibutramine, as compared to placebo, may result in a decrease in post-cessation weight gain in overweight and obese individuals who quit smoking. the use of sibutramine may also result in an increase in smoking cessation rates. design narrative: this study tests the hypothesis that the use of sibutramine, as compared to placebo, will result in a decrease in post-cessation weight gain in overweight and obese individuals who quit smoking, and result in an increase in smoking cessation rates. participants will be randomly assigned to one of the following two groups: 1) sibutramine plus a behavioral smoking cessation program; or 2) placebo sibutramine plus a behavioral smoking cessation program. assessments will include post-cessation weight change and smoking cessation rates measured during the study and 9 months following the end of the study.

Eligibility criteria:
inclusion criteria: * in good general health * body mass index greater than or equal to 25 * currently smoke cigarettes
an observational study of radiotherapy after injection of spaceoar hydrogel

Conditions: Prostate Cancer

Summary: this observational study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized t1-t2 prostate cancer in china who were injected with spaceoar hydrogel, via collecting clinical data related to radiotherapy.

this study protocol is for the second part of spaceoar real world study in which long term follow-up visits will be performed (up to 1 year) outside boao medical tourism pilot zone. the spaceoar real world study is a retrospective and prospective, single arm, observational study (ptotocol of spaceoar rws windchill#: 92743236). subjects with localized t1-t2 prostate cancer who have already been injected with the spaceoar and have received radiotherapy or will receive radiotherapy will be enrolled, and clinical data related to radiotherapy will be collected. for subjects who have already completed radiotherapy before study kick-off, clinical data will be collected retrospectively, such as data related to radiotherapy, ae (if any) and mri (if any). follow up vist will be completed if applicable. for subjects who receive therapy after study kick-off, follow up visits at 2 weeks, 6weeks, 3 months and 10 months after radiotherapy will be scheduled to assess bowel, urinary and sexual function and quality of life.

Eligibility criteria:
inclusion criteria: * subjects have provided the written informed consent, are willing to participate in clinical data collection and willing to comply with study procedure. (for subjects enrolled prospectively) * subjects must have been pathologically confirmed prostate cancer with clinical stage t1-t2, and have been treated with space oar hydrogel, and have received or will receive radiotherapy. exclusion criteria: * all subjects have received radiotherapy or will receive radiotherapy, who have injected with spaceoar hydrogel in boao medical pilot zone. * there is no specific exclusion criteria unless the patients refuse to sign the informed consent.
the real life topical field treatment of actinic keratosis study

Conditions: Actinic Keratosis

Summary: this non-interventional, multinational study of topical field treatment of actinic keratosis (ak) aims to collect real-life experience with ingenol mebutate as well as one or two other topical field therapies commonly used in the individual country. physicians will report baseline characteristics, while the main study focus will be on patient reported outcomes 3-4 weeks after treatment completion (treatment satisfaction, adherence, resource utilization and health related quality of life. dermatology centres in denmark, norway, sweden, the netherlands, the united kingdom and canada will participate.

actinic keratosis (ak) is caused by exposure to uv radiation and has the potential to regress to normal skin or to squamous cell carcinoma. ak treatment options include cryotherapy for solitary lesions and topical field therapy or photodynamic therapy for lesions in an area of sun-damaged skin. this prospective, non-interventional, multinational study aims to describe and compare in a real-life setting the treatment satisfaction, treatment adherence, resource utilization and quality of life during topical field treatment of ak with 5-fluorouracil, imiquimod, diclofenac and ingenol mebutate. dermatology centres in denmark, sweden, norway, canada, the united kingdom and the netherlands will aim to include a total of approximately 1600 patients, of which around 100 in each country will be patients scheduled to receive treatment with ingenol mebutate. in each country patients will in addition be recruited for one or two of the other treatment arms, as appropriate in the country. only adult patients scheduled to start treatment with imiquimod, 5-fluorouracil, diclofenac or ingenol mebutate who have given informed consent to use data from their medical records for the study and to report study data themselves will be included and followed for the duration of the scheduled treatment + 3-4 weeks. physician will report patient demographics and ak characteristics at baseline. patients will at baseline report ak quality of life, including general attitude regarding sun damaged skin at baseline, and, if applicable, treatment satisfaction and adherence with latest previous ak treatment. at 3-4 weeks after end of treatment, the patients will report treatment satisfaction, adherence, resource utilization, health related quality of life. treating physicians report drug-related adverse events in accordance with national laws and regulations and normal clinical practice.

Eligibility criteria:
inclusion criteria: patients eligible to receive topical treatment with one of the following for treatment of actinic keratosis at the discretion of the dermatologist: ingenol mebutate, 5-fluorouracil, imiquimod, diclofenac. informed consent. - exclusion criteria: any on-going treatments at study start with ingenol mebutate, 5-fluorouracil, imiquimod or diclofenac; other topical treatment for ak in treatment area; pregnancy or planned pregnancy within treatment period. -

Keywords: actinic keratosis solar keratosis field treatment ingenol mebutate picato
effectiveness of blood flow restriction exercise therapy to reduce pain in knee osteoarthritis patients

Conditions: Knee Osteoarthritis

Summary: resistance training of knee extensor muscles is being used in physiotherapy management in knee osteoarthritis (oa) to improve pain and physical function. blood flow restriction (bfr) has been suggested to improve pain and increase muscle strength in healthy subjects and certain diseases. although there are clinical studies suggesting improvements in knee osteoarthritis symptoms after 4-12 weeks of exercise with bfr, the acute effects of the intervention have not been known. this study aims to assess the effectiveness of low load exercise therapy combined with bfr on acute pain reduction and within 24 hours post-intervention on people with knee oa compared to a placebo group. this study will take place in athens, greece, as part of the postgraduate msc program of the physiotherapy department of the university of west attica.

a double-blinded randomised clinical trial with a total of 42 participants will be randomly assigned to the intervention (n=21) or the control group (n=21). the intervention group will complete a single exercise session with bfr 80%, 30% 1rm, while the control group will have sham bfr, 30% 1rm. pain pressure threshold (ppt) will be assessed with the use of a digital pressure dynamometer.

Eligibility criteria:
inclusion criteria: * current osteoarthritis clinical diagnosis according to either european league against rheumatism (eular) or american college of rheumatology (acr) criteria * vas/nrs knee pain ≥3/10 during activity exclusion criteria: * previous experience with bfr * has followed knee exercise or kinesiotherapy program in the past 3 months * new medicines in the past 3 months * any lower limb surgery in the past 6 months * knee arthroplasty surgery (knee replacement) * any active healing process affecting walking (fracture, sprain, strain, etc.) * diagnosed with rheumatologic/neurologic disease affecting functionality * diagnosed or history of heart or vascular diseases * diagnosed with respiratory/metabolic disease * personal history of cancer * cognitive problems * pregnancy (only for female participants) * any other indication not to participate in exercise

Keywords: chronic pain